<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Biotherapy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Biotherapy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский биотерапевтический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9784</issn><issn publication-format="electronic">1726-9792</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">28</article-id><article-id pub-id-type="doi">10.17650/1726-9784-2015-14-3-3-18</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОБЗОРЫ ЛИТЕРАТУРЫ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">BIOMARKERS OF DRUG NEPHROTOXICITY</article-title><trans-title-group xml:lang="ru"><trans-title>БИОМАРКЕРЫ ЛЕКАРСТВЕННОЙ НЕФРОТОКСИЧНОСТИ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Osipova</surname><given-names>T. V.</given-names></name><name xml:lang="ru"><surname>Осипова</surname><given-names>Татьяна Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>tvosipova2011@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Bukhman</surname><given-names>V. M.</given-names></name><name xml:lang="ru"><surname>Бухман</surname><given-names>В. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">FSBI «N.N. Blokhin RCRC»</institution></aff><aff><institution xml:lang="ru">ФГБНУ «РОНЦ им. Н.Н. Блохина» МЗ РФ</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2015-09-30" publication-format="electronic"><day>30</day><month>09</month><year>2015</year></pub-date><volume>14</volume><issue>3</issue><issue-title xml:lang="en"/><fpage>3</fpage><lpage>18</lpage><history><date date-type="received" iso-8601-date="2018-04-10"><day>10</day><month>04</month><year>2018</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://bioterapevt.abvpress.ru/jour/article/view/28">https://bioterapevt.abvpress.ru/jour/article/view/28</self-uri><abstract xml:lang="en"><p>Antineoplastic drugs, especially those on the basis of platinum, used for chemotherapy of cancer can also affect various normal tissues and organs including kidneys. Cisplatin occupies one of the leading places and possesses the greatest nephrotoxisity. For many years nephrotoxicity has been evaluated at the level of serum creatinine and of blood urea nitrogen. However these markers have a number of essential shortcomings and do not provide early detection of AKI. To identify early AKI stages new more informative markers are needed, which could make evidence of emerging initial signs of disorders at the earliest and irrespective of filtrational function of kidneys. Characteristics of modern perspective markers of early disoeders of kidneys are presented in the review. Special attention is paid to the panel of markers of potential nephrotoxicity of drugs - candidates for clinical trials, which are recommended for preclinical study. The review presents data of investigations of the role of biomarkers in early diagnostics of AKI caused by cisplatin and its analogues. Use of the ROC analysis in these studies showed that new markers are more sensitive and specific than serum creatinine and blood urea nitrogen and can be used for diagnostics and monitoring of kidney disorders caused by chemotherapeutic drugs.</p></abstract><trans-abstract xml:lang="ru"><p/></trans-abstract><kwd-group xml:lang="ru"><kwd>нефротоксичность</kwd><kwd>цисплатин</kwd><kwd>биомаркёры</kwd><kwd>диагностика</kwd><kwd>nephrotoxicity</kwd><kwd>cisplatin</kwd><kwd>biomarkers</kwd><kwd>diagnostics</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Абаев В.М., Любимова Н.В., Михайлова Л.М. и др. Экспериментальное исследование токсического действия циклоплатама на почки и печень // Вестник РОНЦ им. Н.Н.Блохина РАМН. - 2000. - №3. - С. 43-51.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Вельков В.В., Резникова О.И. Современная лабораторная диагностика ренальных патологий: от ранних стадий до острой почечной недостаточности // Лабораторная диагностика. - 2010. - Т. 4, № 54. - С. 59-65.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Купчан Д.З. Характеристика отдельных противоопухолевых препаратов. Переводчикова Н.И. (ред.) Руководство по химиотерапии опухолевых заболеваний. 3-е изд., доп. и пер. - М.: Практическая медицина, 2011. - С. 72-119.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Кушлинский Н.Е., Любимова Н.В., Дурнов Л.А. и др. Значение ферментурии в оценке нефротоксичности противоопухолевых химиотерапии у детей //БЭБМ- 1997. - №10. - С. 446-50.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Любимова Н.В., Топчиева С.В., Аверинова С.Г. и др. Современные методы диагностики и мониторинга нефротоксичности при проведении противоопухолевой химиотерапии производными платины // БЭБМ. - 2000. - № 9. - С. 317-23.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Поддубная И.В., Орёл Н.Ф. Побочные реакции и осложнения лекарственной терапии. Поражение мочевыводящей системы. Переводчикова Н.И. (ред.) Руководство по химиотерапии опухолевых заболеваний. 3-е изд., доп. и пер. - М.: Практическая медицина, 2011. - С. 425-46; 437-9.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Amin R.P., Vickers A.E., Sistare F. et al. Identification of putative gene based markers of renal toxicity // Environ Health Perspect. - 2004. - 112(4) - P. 465-79.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Bailly V., Zhang Z., Meier W. et al. Shedding of kidney injury molecule 1 a putative adhesion protein involved in renal regeneration // J.Biol.Chem. - 2002. - 277(42). - P. 39739-48.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Basnakian A.G. Netrin 1: universal biomarker for acute kidney injury // Am.J.Physiol.Renal.Physiol. - 2008. - 294(4). - P. F729-30.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Bondiou M.T., Bourbouze R., Bernard M. et al. Inhibition of A and B N-acetyl-beta-D-glucosaminidase urinary isoenzymes by urea // Clin Chim Acta. - 1985. - 149(1). - P. 67-73.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Bonventre J.V., Vaidya V.S., Schmouder R. et al. Next-generation biomarkers for detecting kidney toxicity //Nat.Biotechnol. - 2010. - 28(5). - P. 436-40.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Boulikas T., Vougiouka M._Cisplatin and platinum drugs at the molecular level // Oncol.Rep. - 2003. -10(6). - P. 1663-82.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Chinery R., Poulsom R., Elia G. et al. Expression and purification of a trefoil peptide motif in a beta-galactosidase fusion protein and its use to search for trefoil-binding sites // Eur.J.Biochem. - 1993. - 212. -P. 557-63.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Chiusolo A., Defazio R., Zanetti E. et.al. Kidney injury molecule 1 expression in rat proximal tubule after treatment with segment-specific nephrotoxicants: A tool for early screening of potential kidney toxicity // Toxicol Pathology. - 2010. - 38(3). - P. 338-45.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Coca S.G., Parikh C.R. Urinary biomarkers for acute kidney injury: perspectives on translation // Clin. J. Am. Soc. Nephrol. - 2008. - 3(2). - P. 481-90.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Correa-Roffer R. Induction of clasterin in tubules of nephritic rats // J.Am.Soc.Nephrol. - 1998. - 9. - P. 33-7.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Cristofori P., Zanetti E., Fregona D. et al. Renal proximal tubule segment-specific nefrotoxicity: An review on biomarkers and histopatology // Toxicologic Pathology. - 2007. - 35. - P. 270-5.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Critical Path Institute. Letter of support for two rodent kidney safety biomarkers // 2014. http://c-path. org/programs/pstc/regulatory-successes/</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>de Geus H.R., Betjes M.G., Bakker J. Biomarkers for prediction of acute kidney injury: narrative review on current status and future challenges // Clin.Kidney J. - 2012. - 5. - P. 102-8.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Devarajan P. Emerging urinary biomarkers in the diagnosis of acute kidney injury // Expert.Opin.Med.Diag. - 2008. - 2(4). - P. 387-98.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Devarajan P. Emerging biomarkers for the early detection of acute kidney injury // Nephrology. - 2010. -5(2). - P. 38-44.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Devarajan P., Tarabishi R., Mishra J. et al. Low renal toxicity of lipoplatin compared to cisplatin in animals //Anticancer Res. - 2004. - 24 (4). - P. 2193-200.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Dharnidharka V.R., Kwon C., Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis // J. Kidney Dis. - 2002. - 40(2). - P. 221-6.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Dieterle F., Marrer E., Suzuki E. et al. Monitoring kidney safety in drug development: emerging technologies and their implication // Curr.Opin.Drug Discov.Devel. - 2008. - 11(1). - P. 60-71.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Dieterle F., Perentes E., Cordier A. et.al. Urinary clasterin, ß2-micriglobulin and total protein as markers to detect drug-induced kidney injury // Nat.Biotethnol. - 2010. - 28. - P. 463-9.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Dodiya H., Mukul J., Goswami S. Study of urinary biomarkers for nephrotoxicity in Wistar rats // J.Pharmacol.Toxicol. - 2011. - 6(6). - P. 571-9.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Falkenberg F.W., Hildebrand H., Lutte L. et al. Urinary antigens as markers of papillary toxicicity: I. Identification and characterization of rats kidney papillary antigens with monoclonal antibodies // Arch. Toxicol. - 1996. - 71(1-2). - P. 80-92.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Faubel S., Lewis E.C., Reznikov L. et al. Cisplatin induced acute renal failure is associated with an increase in the cytokines interlekin IL-1ß, IL18, IL6, and neuthil infiltration in the kidney // J.Pharmacol.Exp.Ther. -2007. - 322 (1). - P. 8-15.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Feinfeld D.A., Fuh V.L., Safirstein R. Urinary glutathione-S-transferase in cisplatin nephrotoxicity in the rat // J Clin Chem Clin Biochem. - 1986. - 24(8). - P. 529-32.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Fuchs T.C., Hewitt P. Biomarkers for drug-induced damage and nephrotoxicity. An overview for applied toxicology // The AAPS Journal. - 2011. - 13(4). - P. 615-31.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Gaspari F., Cravedi P., Mandalà M. et al. Predicting cisplatin-induced acute kidney injury neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case-control study // Nephron.Clin.Pract. - 2010. -115(2). - P. 154-60.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Gautier J.C., Riefke B., Walter J. et al. Evaluation of new biomarkers of nephrotoxicity in two strains of rat treated with cisplatin // Toxicology Pathology. - 2010. - 38(6). - P. 943-56.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Han W.K., Bailly V., Abichandani R. et al. Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury kidney // Kidney International. - 2002. - 62. - P. 237-44.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Han W.K., Waikar S.S., Johnson A. et al. Urinary biomarkers in the early diagnosis of acute kidney injury // Kidney International. - 2008. - 73. - P. 863-9.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Harpur E., Ennulat D., Hoffman D. et al. Biological quantification of biomarkers of chemical-induced renal toxicity in two strains of male rat // Toxicological Sciences. - 2011. - 122(2). - P. 235-52.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Harrison D.J., Kharbanda R., Cunningham D.S. et al. Distribution of glutathione-S-transferase isoenzymes in human kidney: basis for possible markers of renal injury // J. Clin.Pathol. - 1989. - 42. - P. 624-8.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Hofmeister R., Bhargava A.S., Günzel P. Value of enzyme determinations in urine for the diagnosis of nephrotoxicity in rats // Clin. Chim. Acta. - 1986. - 160(2). - P. 163-7.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Honore P.M., Joannes-Boyau O., Boer W. et al. The early biomarker of acute kidney injury: in search of the Holy Grall //Intensive Care Med. - 2007. - 33. - P. 1866-8.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Huang Q., Dunn R.T., Jayadev S. et al. Assessment of cisplatin-induced nephrotoxicity by microarray technology // Toxicol. Sci. - 2001. - 63(2). - P. 196-207.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Ichimura T., Hung C.C., Yang S.A. et al. Kidney injury molecule-1 a tissue and urinary biomarker for nephrotoxicant-induced renal injury //Am.J.Physiol.Renal.Physiol. - 2004. - 286. - P. F552-63.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Khan E., Batuman V., Lertora J.J. Emergence of biomarkers in nephropharmacology // Biomark. Med. - 2010. - 4(6). - P. 805-14.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Kilty C., Doyle S., Hassett B. et al. Glutation-S- transferases as biomarkers of organ damage: application of rodent and canine Г-S-T enzyme immunoassays // Chem.Biol.Interact - 1998. - 111-112. - P. 123-5.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Kondo C., Minowa Y., Uehara T. et al. Identification of genomic biomarkers for concurrent diagnosis of drug induced renal tubular injury using a large-scale toxicogenomic database // Toxicology. - 2009. -265(1-2). - P. 15-26.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Kos F.T., Sendur M.A., Aksoy S. et al. Evaluation of renal function using the level of Neutrophil gelatinase-associated lipocalin is not predictive of nephrotoxicity associated with cisplatin-based chemotherapy // Asian Pac. J. Cancer Prev. - 2013. - 14(2). - P. 1111-4.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Kurschel E., Metz-Kurschel U., Niederle N. et al. Investigations on the subclinical and clinical nephrotoxicity of interferon-a2B in patients with myeloproliferative syndromes //Ren.Fail. - 1991. - 13. - P. 87-93.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Lisowska-Myjak B. Serum and urinary biomarkers of acute kidney injury // Blood Purif - 2010. - 29. - P. 357-65.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Litterst C.L., Gram T.E., Dedrick R.L. et al. Distribution and disposition of platinum following intravenous administration of cis-diamminedichloroplatinum(II) (NSC 119875) to dogs // Cancer Res. - 1976. - 36(7 PT 1). P. 2340-4.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Litterst C.L, LeRoy A.F., Guarino A.M. Disposition and distribution of platinum following parenteral administration of cis-dichlorodiammineplatinum(II) to animals // Cancer Treat Rep. - 1979. - 63(9-10). - P. 1485-92.</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Lock E.A. Toxicolocical highlight. Sensitive and early markers of renal injury. Where are we and what is the way forward? // Toxicological Sciences. - 2010. - 116(1). - P. 1-4.</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Ludwig T., Riethmüller C., Gekle M. et al. Nephrotoxicity of platinum complexes is related to basolateral organic cation transport // Kidney International. - 2004. - 66. - P. 196-202.</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Maatman R.G., van de Westerlo E.M., van Kuppevelt T.H. et al. Molecular identification of the liver and heart-type fatty acid-binding protein in human and rat kidney. Use of the reverse transcriptase polymerase chain reaction //Biochem.J. -1992. - 288(Pt.1). -P. 285-90.</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Mårtensson J., Martling C.R., Bell M. Novel biomarkers of acute kidney injury and failure: clinical applica bility // Brit.J.Anestesia. - 2012. - 109(6). - P. 843-50.</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Mc Duffie J.E., Ma J.Y., Sablab M. et al. Time course of renal proximal tubule injury reversal and related biomarker changes in rats following cisplatin administration // Int.J. Toxicol. - 2013. - 32(4). - P. 251-60.</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Mishra J., Ma Q., Prada A. et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal inury // J.Am.Soc.Nephrol. -2003. -14(10). -P. 2534-43.</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Mishra J., Mori K., Ma Q. et al. Neutrophil gelatinase-associated lipocalin a novel early urinary biomarkers for cisplatin nephrotoxicity// Am.J.Nephrol. -2004. -24(3). -P. 307-15.</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Mishra J., Mori K., Ma Q._et al. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin // Am.J.Soc.Nephrol. -2004. -15. -P. 3073-82.</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Mishra J., Ma Q., Kelly C. et al. Kidney NGAL is a novel early marker of acute injury following transplantation // Pediator.Nephrol. - 2006. - 21. - P. 856-63.</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Moran S.M., Myers B.D. Course of acute renal of feature studied by a model of creatinine kinetics // Kidney International. - 1985. - 27. - P. 928-37.</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Naidu S.G., Lee F.T. Contrast nephrotoxicity: predictive value of urinary enzyme markers in a rat model // Acad.Radiol. - 1994. - 1(1). - P. 3-9.</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Nasri H. Comment on: A model for prediction of cisplatin-induced nephrotoxicity by kidney weight in experimental rats // J.Res.Med. Sciences. - 2013. - 18(12). - P. 1119-200.</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Negishi K., Noiri E., Doi K._et al. Monitoring urinary L-type fatty acid binding protein predicts histological severity of acute kidney injury //Amer.J. Pathology. -2009. -174(4). -P. 1154-9.</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>Osman N.M., Litterst C.L. Effect of probenecid and N'-methylnicotinamide on renal handling of cisdichlorodiammineplatinum-II in rats // Cancer Lett. - 1983. - 19(1). - P. 107-11.</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>Ostermann M., Philips B.J., Forni L.G. Clinical review. Biomarkers of acute kidney injury: Where are we now? // Critical Care. - 2012. - 16. - P. 233.</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>Parikh C.R., Jani A., Melnikov V.Y._et al. Urinary IL18 is a marker of human acute tubular necrosis // Am.J.Kidney Dis. - 2004. - 43. - P. 405-14.</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>Pasetto L.M., D'Andrea M.R., Brandes A.A. et al. The development of platinum compounds and their possible combination // Crit.Rev.Oncol.Hematol. -2006. -60. -P. 59-75.</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>Perazella M.A., Moeckel G.W. Nephrotoxicity from chemotherapeutic agents: clinical manifestations pathobiology and prevention therapy // Semin. Nephrology. -2010. -30(6). -P. 570-81.</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation>Pinches M., Betts C., Bickerton S. et.al. Evaluation of novel renal biomarkers with cisplatin model of kidney injury: gender and dosage differences // Toxicol.Pathol. - 2012. - 40. - P. 522-33.</mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation>Portilla D., Li S., Nagothu K.K. et al. Metabolomic study of cisplatin-induced nephrotoxicity //Kidney Int. - 2006. -69. -P. 2194-204.</mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation>Portilla D., Schnackenberg L., Beger R.D. Metabolomics as an extension of proteomic analysis: study of acute kidney injury // Semin Nephrol. - 2007 - 27. - P. 609-20.</mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation>Price R.G. The role NAG (N-acetyl-beta-D-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity // Clin.Nephrol. - 1992. - 38(suppl.1). - P. S14-9.</mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation>Reeves W.B., Kwon O., Ramesh G. Netrin 1 and kidney injury. II. Netrin 1 as an early biomarkers of acute kidney injury //Am.J.Physiol.Renal.Phisiol. -2008. -294. -P. F731-8.</mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation>Rosenberg M.E., Silkensen J. Clusterin: physiologic and phatophysiologic considerations // Int.J.Biochem.Cell.Biol. -1995. -27. -P. 633-45.</mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation>Safirstein R., Winston J., Goldstein M. et al. Cisplatin nephrotoxicity //Am.J. Kidney Dis. - 1986. - 8. - P. 356-67.</mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation>Sahni V., Choudhury D., Ahmed Z._et al. Chemotherapy-associated renal dysfunction //Nat.Rev.Nephrol. - 2009. -5(8). -P. 450-62.</mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation>Saleena U.V., Athiyamaan M., Vadhiraja B.M. et al. Urinary a-glutathione-s-transferase variations in cisplatin treated cancer patients with and without kidney injury // Internat.Conf on Bioscience, Biochemistry, Bioinformatics. IPCBEE. - 2012 - 31. - P. 32-9.</mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation>Schentag J.J. Specificity of renal tubulare damage criteria for aminoglycoside nephrotoxicity in criticcaly ill patients// J.Clin.Pharmacol. - 1983. - 23(10). - P. 473-83.</mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation>Schmidt-Ott K.M., Mori K., Kalandadze A. et al. Neutrophil gelatinase-associated lipocalin- mediated iron traffic in kidney epithelia//Curr.Opin.Nephrol.Hypertens. -2006. -15(4). -P. 442-9.</mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation>Taguchi T., Razzaque M.S. Cisplatin-associated nephrotoxicity and pathological events. Razzague MS, Taguchi T (eds): Cellular stress responses in renal diseases. Contrub.Nephrol. Basel: Karger, 2005. - 148. - P. 106-20.</mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation>Tesch G.H. Serum and urine biomarkers of kidney disease: A pathophysiological perspective // Nephrology. - 2010. - 15. - P. 609-16.</mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation>Thompson K.L., Afshari C.A., Amin R.P. et al. Identification of platform-independent gene expression markers of cisplatin nephrotoxicity // Enviromental Health Perspectives. - 2004. - 119(4). - P 488-94.</mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation>Thukral S.K., Nordone P.J., Hu R. et al. Prediction of nephrotoxicant action and identification of candidate toxicity-related biomarkers // Toxicol. Pathol. -2005. -33. -P. 343-55.</mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation>Tonomura Y., Tsuchiya N., Torii M. et al. Evaluation of the usefulness of urinary biomarkers for nephrotoxicity in rats // Toxicology. -2010. -273. - P. 53-9.</mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation>Trevisan A., Cristofori P., Fanelli G.jGlutamine syntetase activity in rat urine as sensitive marker to detect S3 segment specific injury of proximal tubule induced by xenobiotics // Arch. Toxicol. - 1999. - 73(4-5). -P. 255-62.</mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation>Uchida K., Gotoh A. Measurement of cystatin C and creatinine in urine // Clin. Chem.Acta. - 2002. - 323. -P. 121-8.</mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation>Uehara T., Watanabe H., Itoh F. et al. Nephrotoxicity of a novel antineoplastic platinum complex nedaplatin: a comparative study with cisplatin in rats// Arch.Toxicol. -2005. - 79(8). -P. 451-60.</mixed-citation></ref><ref id="B86"><label>86.</label><mixed-citation>Uehara T., Yamate J., Torii M. et al. Comparative nephrotoxicity of cisplatin and nedaplatin mechanisms andhistopathological characteristic//J.Toxicol.Patol. -2011. -24. -P. 87-94.</mixed-citation></ref><ref id="B87"><label>87.</label><mixed-citation>Vaidya V.S., Ramirez V., Ichimura T. et al. Urinary kidney injury molecule 1: a sensitive quantitative biomarker for early detection of kidney tubular injury // Am.J.Physiol.Renal.Physiol. - 2006. - 290(2). - P. F517-29.</mixed-citation></ref><ref id="B88"><label>88.</label><mixed-citation>Vaidya V.S., Ferguson M.A., Bonventre J.V. Biomarkers of acute kidney injury // Annu.Rev.Pharmacol.Toxicol. -2008. -48. -P. 463-8.</mixed-citation></ref><ref id="B89"><label>89.</label><mixed-citation>Vaidya V.S., Ozer J.S., Frank D. et al. Kidney injury molecule 1 outperforms traditional biomarkers of kidney injury in multi-site preclinical biomarker qualification studies // Nat.Biotechnol. - 2010. - 28(5). - P. 478-85.</mixed-citation></ref><ref id="B90"><label>90.</label><mixed-citation>Vinken P., Starckx S., Barale-Thomas E. et al. Tissue kim-1 and urinary clasterin as early indicators of cisplatin-induced acute kidney injury in rats // Toxcol.Pathol. -2012. -40(7). -P. 1049-62.</mixed-citation></ref><ref id="B91"><label>91.</label><mixed-citation>Westhuyzen J., Endre Z.H., Reece G. et al. Measurement of tubular enzymuria facilitates early detection of acute renal impairment in the intensive care unit //Nephrol Dial Transplant. - 2003. - 18(3). - P. 543-51.</mixed-citation></ref><ref id="B92"><label>92.</label><mixed-citation>Whiting P.H., Brown P.A. The relation between enzymuria and kidney enzyme activities in experimental gentamicin nephrotoxicity//Ren.Tail. -1996. -18(6). -P. 899-909.</mixed-citation></ref><ref id="B93"><label>93.</label><mixed-citation>Wolfgang G.H., Dominick M.A., Walsh K.M. et al. Comparative nephrotoxicity of a novel platinum compound cisplatin and carboplatin in male Wistar rats//Fund.Appl.Toxicology. -1994. -22(1). -P. 73-9.</mixed-citation></ref><ref id="B94"><label>94.</label><mixed-citation>Yamate J., Tatsumi M., Nakatsuji S. et al. Immunohistochemical observations on the kinetics of macrophages and myofibroblasts in rat renal interstitial fibrosis induced by cis-diamminedichloroplatinum // J. Compar. Phatol. - 1995. - 112(1). - 27-39.</mixed-citation></ref><ref id="B95"><label>95.</label><mixed-citation>Yano R., Golbar H.M., Izawa T. et al. Participation of bone morphogenetic protein (BMP)-6 and osteopontin in cisplatin (CDDP)-induced rat renal fibrosis // Exp Toxicol Pathol. - 2015. - 67(2). -P. 99-107.</mixed-citation></ref><ref id="B96"><label>96.</label><mixed-citation>Yu Y., Jin H., Holder D._et al. Urinary biomarkers trefoil factor 3 and albumine enable early detection of kidney tubular injury//Nat. Biotechnol. -2010. -28(5). -P. 470-7.</mixed-citation></ref><ref id="B97"><label>97.</label><mixed-citation>Zhou Y., Vaidya V.S., Brown R.P. et al. Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium // Toxicol Sci. - 2008. - 101(1). - P. 159-70.</mixed-citation></ref></ref-list></back></article>
